Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes

AIMS: Most trials leading to the approval of glucagon‐like peptide receptor agonists (GLP‐1RAs) and sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) were primarily designed to confirm their non‐inferiority to placebo (commonly using an upper 95% confidence limit threshold of 1.3) and, if confirm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaccardi, Francesco, Kloecker, David E., Khunti, Kamlesh, Davies, Melanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543971/
https://www.ncbi.nlm.nih.gov/pubmed/35491523
http://dx.doi.org/10.1111/dom.14735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543971/
https://www.ncbi.nlm.nih.gov/pubmed/35491523
http://dx.doi.org/10.1111/dom.14735

Ejemplares similares